Coronavirus Disease 2019 (COVID-19) World

World Health
Health
Coronavirus Disease
Coronavirus Disease 20192019 (COVID-19)
(COVID-19) Organization
Organization
SituationReport
Situation Report--749 Indonesia
Indonesia

31 March
Data 2021
as of 07 May 2020

HIGHLIGHTS

• As of 31 March, the Government of Indonesia reported

1 511 712 (5937 new) confirmed cases of COVID-19, 40 858
(104 new) deaths and 1 348 330 recovered cases from 510
districts across all 34 provinces.1

• WHO continues to support the National Institute of Health

Research and Development to strengthen quality assurance
systems in COVID-19 testing laboratories (page 16).

• WHO supported the Ministry of Health to review the

implementation of the Indonesian Electronic Health Alert
Card (eHAC) and conduct a refresher training on eHAC
application in East Java (page 17).

Fig. 1. Geographic distribution of cumulative number of confirmed COVID-19 cases in Indonesia across
the provinces reported from 25 to 31 March 2021. Source of data

Disclaimer: The number of cases reported daily is not equivalent to the number of persons who contracted
COVID-19 on that day; reporting of laboratory-confirmed results may take up to one week from the time of testing.

1
https://covid19.go.id/peta-sebaran-covid19
1
WHO Indonesia Situation Report - 49
who.int/indonesia
 GENERAL UPDATES

• State-owned pharmaceutical company, Bio Farma, announced that it had

distributed 5000 vials of AstraZeneca COVID-19 vaccine to each province, namely
DKI Jakarta, North Sulawesi and Riau Islands on 29 March. Previously, the
company distributed 45 000 vials of the vaccine to East Java. Each vial consists
of 10 doses. The spokesperson of Bio Farma said that the Ministry of Health (MoH)
had instructed the company to distribute AstraZeneca COVID-19 vaccines to
several provinces including Bali, DKI Jakarta, East Nusa Tenggara, North
Sulawesi and Riau Islands. The company is awaiting further instructions from MoH
on the distribution of the remaining vials.2

• On 27 March, the Minister of Health stated that Indonesia will ration its vaccine use
in response to expected delays in the shipments of AstraZeneca COVID-19
vaccine from the COVAX Facility and a slowdown in the production of Sinovac
vaccine manufactured by Bio Farma. Initially, Indonesia was expected to receive
a shipment of 10 million doses of AstraZeneca vaccine in March and April. In
addition, the Minister said that the country would only have around 7.6 million
ready-to-use Sinovac vaccines manufactured by Bio Farma available in April
2021.3

• During a virtual press conference on 27 March, the Minister of Health said that
COVID-19 vaccination for those aged 60 years and above has been rolled out
slower than expected. He mentioned that the low vaccination rate in this priority
group is due to several reasons, including vaccine hesitancy and limited mobility.
To address this issue, MoH is considering several options to ensure easier access
for older populations to receive their vaccination and boost national vaccination
coverage.4

• On 26 March, the Coordinating Minister for Human Development and Cultural

Affairs announced that the Government will ban the Eid al-Fitr tradition of mudik
(returning to hometowns for Eid) in 2021. The ban is intended to prevent a spike
in COVID-19 transmission and deaths after the holiday. Furthermore, he explained
that the ban is effective for civil servants, military personnel, police and the general
public. In addition, regulations specifying the mobility restrictions during the ban
will be issued by related authorities after coordinating with the National COVID-19
Task Force.5

2
https://www.thejakartapost.com/paper/2021/03/25/following-mui-fatwa-astrazeneca-jabs-sent-to-regions.html
3
https://www.thejakartapost.com/paper/2021/03/28/indonesia-slows-down-vaccine-rollout-amid-delayed-
supplies.html
4
https://nasional.kompas.com/read/2021/03/27/23254081/menkes-vaksinasi-covid-19-untuk-lansia-di-beberapa-
provinsi-masih-rendah
5
https://www.thejakartapost.com/paper/2021/03/28/govt-to-ban-idul-fitri-exodus-again-this-year.html
2
WHO Indonesia Situation Report - 49
who.int/indonesia
 SURVEILLANCE

• On 31 March, 5937 new and 1 511 712 cumulative confirmed COVID-19 cases were
reported nationwide (Fig. 2). The average for the last seven days from 25 to 31
March was 5037 per day, compared to 5596 cases per day reported in the previous
week.

16000 1600000

14000 1400000

12000 1200000

Cumulative number
Daily number

10000 1000000

8000 800000

6000 600000

4000 400000

2000 200000

0 0
23-Nov
3-Aug

7-Dec

4-Jan
2-Mar

14-Sep
28-Sep

15-Feb
1-Mar
16-Mar

8-Jun

18-Jan
6-Jul

9-Nov
30-Mar

1-Feb
13-Apr
27-Apr
11-May
25-May

22-Jun

15-Mar
29-Mar
17-Aug
31-Aug

21-Dec
20-Jul

12-Oct
26-Oct

Daily number of confirmed COVID-19 cases Cumulative number of confirmed COVID-19 cases

Fig. 2. Daily and cumulative number of cases reported in Indonesia, as of 31 March 2021.
Source of data

Disclaimer: The number of cases reported daily is not the number of persons who contracted
COVID-19 on that day and might be influenced by the number of people tested on that day (see Fig. 17);
reporting of laboratory-confirmed results may take up to one week from the time of testing. Therefore,
caution must be taken in interpreting this figure and the epidemiological curve for further analysis, either
at the national or subnational level.

3
WHO Indonesia Situation Report - 49
who.int/indonesia
 • During the week of 22 to 28 March, the provinces of Maluku, Riau Islands, Aceh,
North Sulawesi and South Sumatra experienced an increase in the number of
weekly cases of more than 50% compared to the previous week (Fig. 3). It is critical
to investigate reasons for the increase in new confirmed cases to guide decisions
on response activities and inform the adjustment of public health and social
measures (PHSM).6

Maluku
Riau Islands
Aceh
North Sulawesi
South Sumatra
Central Sulawesi
Jambi
South Kalimantan
Riau
North Kalimantan
West Sumatra
Central Kalimantan
Papua
Gorontalo
DI Yogyakarta
North Sumatra
Bengkulu
East Java
Bali
Lampung
Bangka Belitung Islands
East Kalimantan
West Nusa Tenggara
DKI Jakarta
West Java
Central Java
West Papua
West Kalimantan
Banten
East Nusa Tenggara
South Sulawesi
North Maluku
Southeast Sulawesi
West Sulawesi

-100% -50% 0% 50% 100% 150%

Percentage change of weekly number of confirmed cases
Fig. 3. Percentage change of weekly number of confirmed cases by province during 22 to 28
March 2021 compared to the previous week. Source of data

Disclaimer: The number of weekly confirmed cases is calculated taking into consideration the daily
number of reported cases. Caution should be exercised when interpreting this figure due to data
limitations reported by MoH.

6
It is also important to conduct further investigation if there is a substantial decrease in new cases, especially in
provinces with 50% or more decline. Other indicators, such as testing and contact tracing, may help elucidate the
reasons behind a drop in new cases.
4
WHO Indonesia Situation Report - 49
who.int/indonesia
 • During the week of 22 to 28 March, the incidence7 of COVID-19 in Indonesia was
14.4 per 100 000 population, compared to 15.2 per 100 000 in the previous week
(Fig. 4).
35

30

CT2 (20 - <50)

25
Case incidence

20

15

10 CT1 (<20)

0
13/04 - 19/04
27/04 - 03/05
11/05 - 17/05
25/05 - 31/05
08/06 - 14/06
22/06 - 28/06
06/07 - 12/07
20/07 - 26/07
03/08 - 09/08
17/08 - 23/08
31/08 - 06/09
14/09 - 20/09
28/09 - 04/10
12/10 - 18/10
26/10 - 01/11
09/11 - 15/11
23/11 - 29/11
07/12 - 13/12
21/12 - 27/12
04/01 - 10/01
18/01 - 24/01
01/02 - 07/02
15/02 - 21/02
01/03 - 07/03
15/03 - 21/03
Fig. 4. Incidence of COVID-19 per 100 000 population per week averaged over a two-week period
reported in Indonesia from 13 April 2020 (when Indonesia first reported community transmission in
the country) to 28 March 2021, classified by level of community transmission (CT): CT1: low
incidence; CT2: moderate incidence; CT3: high incidence; CT4: very high incidence. Source of data

Disclaimer: There are seven categories for transmission classification: (1) no (active) cases; (2)
imported/sporadic cases; (3) cluster of cases; (4) community transmission 1 (CT1); (5) community
transmission 2 (CT2); (6) community transmission 3 (CT3); and (7) community transmission 4
(CT4).
Caution should be exercised when interpreting this indicator due to limitations listed in the
WHO interim guidance. Other limitations include data incompleteness and data quality issues
reported by MoH. Other epidemiological indicators also need to be evaluated to decide on the level
of community transmission. This disclaimer applies to indicators at national (Fig. 4) and subnational
levels (Figs. 5 to 11).

7
Weekly incidence of COVID-19 is calculated as the number of new cases per 100 000 population per
week averaged over a two-week period. Source of population data
5
WHO Indonesia Situation Report - 49
who.int/indonesia
 • During the week of 22 to 28 March, the incidence of COVID-19 per 100 000
population was 92.1 in DKI Jakarta, which corresponds to community transmission
level 3 (Fig. 5). Based on WHO interim guidance, community transmission level 3
means that there is a high risk of COVID-19 infection for the general population
and that a high incidence of locally acquired, widely dispersed cases was detected
in the past 14 days.

DKI Jakarta
East Kalimantan
North Kalimantan
Bangka Belitung Islands
DI Yogyakarta
South Kalimantan
Central Kalimantan
Bali
West Papua
Banten
West Java
East Nusa Tenggara
Papua
Riau
West Sumatra
Central Java
Central Sulawesi
Gorontalo
South Sulawesi
West Kalimantan
North Maluku
Bengkulu
East Java
Riau Islands
West Nusa Tenggara
Jambi
South Sumatra
North Sumatra
Maluku
Lampung
North Sulawesi
Southeast Sulawesi
West Sulawesi
Aceh

0.0 50.0 100.0 150.0

Weekly case incidence

CT 1 (<20) CT 2 (20-<50) CT 3 (50 - <150) CT 4 (150+)

Fig. 5. Incidence of COVID-19 per 100 000 population per week averaged over a two-week period
by province in Indonesia during 22 to 28 March 2021, classified by level of community transmission
(CT): CT1: low incidence; CT2: moderate incidence; CT3: high incidence; CT4: very high incidence.
Source of data

6
WHO Indonesia Situation Report - 49
who.int/indonesia
 • The weekly incidence of COVID-19 decreased in all provinces in Java Island
except DI Yogyakarta and Banten during the week of 22 to 28 March compared to
the previous week (Fig. 6 to 11).
DKI Jakarta
240

200 CT4 (150+)

Case incidence

160

120
CT3 (50 - <150)
80

40 CT2 (20 - <50)

CT1 (<20)
0
06/07 - 12/07
13/04 - 19/04

27/04 - 03/05

11/05 - 17/05

25/05 - 31/05

08/06 - 14/06

22/06 - 28/06

20/07 - 26/07

03/08 - 09/08

17/08 - 23/08

31/08 - 06/09

14/09 - 20/09

28/09 - 04/10

12/10 - 18/10

26/10 - 01/11

09/11 - 15/11

23/11 - 29/11

07/12 - 13/12

21/12 - 27/12

04/01 - 10/01

18/01 - 24/01

01/02 - 07/02

15/02 - 21/02

01/03 - 07/03

15/03 - 21/03
Fig. 6. Incidence of COVID-19 per 100 000 population per week averaged over a two-week period
in DKI Jakarta, from 13 April 2020 to 28 March 2021, classified by level of community transmission
(CT): CT1: low incidence; CT2: moderate incidence; CT3: high incidence; CT4: very high incidence.
Source of data

West Java
45
40 CT 2 (20 - <50)
35
Case incidence

30
25
20
15
10
CT 1 (<20)
5
0
25/05 - 31/05

31/08 - 06/09

07/12 - 13/12
13/04 - 19/04

27/04 - 03/05

11/05 - 17/05

08/06 - 14/06

22/06 - 28/06

06/07 - 12/07

20/07 - 26/07

03/08 - 09/08

17/08 - 23/08

14/09 - 20/09

28/09 - 04/10

12/10 - 18/10

26/10 - 01/11

09/11 - 15/11

23/11 - 29/11

21/12 - 27/12

04/01 - 10/01

18/01 - 24/01

01/02 - 07/02

15/02 - 21/02

01/03 - 07/03

15/03 - 21/03

Fig. 7. Incidence of COVID-19 per 100 000 population per week averaged over a two-week period
in West Java, from 13 April 2020 to 28 March 2021, classified by level of community transmission
(CT): CT1: low incidence; CT2: moderate incidence; CT3: high incidence; CT4: very high incidence.
Source of data
7
WHO Indonesia Situation Report - 49
Fig. 6. Incidence of COVID-19 per 100 000 population per week averaged over a two-week period
who.int/indonesia
in West Java, from 13 April 2020 to 24 January 2021, classified by level of community transmission
(CT): CT1: low incidence; CT2: moderate incidence; CT3: high incidence; CT4: very high incidence.
 Central Java
40
35 CT 2 (20 - <50)

30
Case incidence

25
20
15
10
CT 1 (<20)
5
0
13/04 - 19/04

27/04 - 03/05

11/05 - 17/05

25/05 - 31/05

08/06 - 14/06

22/06 - 28/06

06/07 - 12/07

20/07 - 26/07

03/08 - 09/08

17/08 - 23/08

31/08 - 06/09

14/09 - 20/09

28/09 - 04/10

12/10 - 18/10

26/10 - 01/11

09/11 - 15/11

23/11 - 29/11

07/12 - 13/12

21/12 - 27/12

04/01 - 10/01

18/01 - 24/01

01/02 - 07/02

15/02 - 21/02

01/03 - 07/03

15/03 - 21/03
Fig. 8. Incidence of COVID-19 per 100 000 population per week averaged over a two-week period
in Central Java, from 13 April 2020 to 28 March 2021, classified by level of community transmission
(CT): CT1: low incidence; CT2: moderate incidence; CT3: high incidence; CT4: very high incidence.
Source of data

DI Yogyakarta
70
CT 3 (50 - <150)
60

50
Case incidence

40
CT 2 (20 - <50)
30

20

10 CT 1 (<20)

0
13/04 - 19/04

27/04 - 03/05

11/05 - 17/05

25/05 - 31/05

08/06 - 14/06

22/06 - 28/06

06/07 - 12/07

20/07 - 26/07

03/08 - 09/08

17/08 - 23/08

31/08 - 06/09

14/09 - 20/09

28/09 - 04/10

12/10 - 18/10

26/10 - 01/11

09/11 - 15/11

23/11 - 29/11

07/12 - 13/12

21/12 - 27/12

04/01 - 10/01

18/01 - 24/01

01/02 - 07/02

15/02 - 21/02

01/03 - 07/03

15/03 - 21/03

Fig. 9. Incidence of COVID-19 per 100 000 population per week averaged over a two-week period
in DI Yogyakarta, from 13 April 2020 to 28 March 2021, classified by level of community transmission
(CT): CT1: low incidence; CT2: moderate incidence; CT3: high incidence; CT4: very high incidence.
Source of data

8
WHO Indonesia Situation Report - 49
who.int/indonesia
 East Java
20
18
16
14
Case incidence

12
10 CT 1 (<20)
8
6
4
2
0
06/07 - 12/07

12/10 - 18/10

18/01 - 24/01
13/04 - 19/04

27/04 - 03/05

11/05 - 17/05

25/05 - 31/05

08/06 - 14/06

22/06 - 28/06

20/07 - 26/07

03/08 - 09/08

17/08 - 23/08

31/08 - 06/09

14/09 - 20/09

28/09 - 04/10

26/10 - 01/11

09/11 - 15/11

23/11 - 29/11

07/12 - 13/12

21/12 - 27/12

04/01 - 10/01

01/02 - 07/02

15/02 - 21/02

01/03 - 07/03

15/03 - 21/03
Fig. 10. Incidence of COVID-19 per 100 000 population per week averaged over a two-week period
in East Java, from 13 April 2020 to 28 March 2021, classified by level of community transmission
(CT): CT1: low incidence; CT2: moderate incidence; CT3: high incidence; CT4: very high incidence.
Source of data

Banten
20
18
16
14
Case incidence

12
10 CT 1 (<20)
8
6
4
2
0
13/04 - 19/04
27/04 - 03/05
11/05 - 17/05
25/05 - 31/05
08/06 - 14/06
22/06 - 28/06
06/07 - 12/07
20/07 - 26/07
03/08 - 09/08
17/08 - 23/08
31/08 - 06/09
14/09 - 20/09
28/09 - 04/10
12/10 - 18/10
26/10 - 01/11
09/11 - 15/11
23/11 - 29/11
07/12 - 13/12
21/12 - 27/12
04/01 - 10/01
18/01 - 24/01
01/02 - 07/02
15/02 - 21/02
01/03 - 07/03
15/03 - 21/03

Fig. 11. Incidence of COVID-19 per 100 000 population per week averaged over a two-week period
in Banten, from 13 April 2020 to 28 March 2021, classified by level of community transmission (CT):
CT1: low incidence; CT2: moderate incidence; CT3: high incidence; CT4: very high incidence.
Source of data

9
WHO Indonesia Situation Report - 49
who.int/indonesia
 • Test positivity proportion nationwide increased sharply after 23 November and
reached a peak of 30.5% in mid-February. Subsequently, the positivity proportion
declined and stood at 12.8% on 28 March (Fig. 12). However, the percentage of
positive samples can be interpreted reliably only with comprehensive surveillance
and testing in the order of one person tested per 1000 population per week. This
minimum case detection benchmark was achieved in DKI Jakarta, DI Yogyakarta,
and Banten for the last three weeks, but none of these provinces had a test positivity
proportion of less than 5% (Fig. 13).

40%

35%
CT 4 (20%+)
30%
Positivity proportion (%)

25%

20%

CT 3 (5% - <20%)
15%

10%

5%
CT 2 (2% - <5%)
CT 1 (<2%)
0%
1-May 1-Jun 1-Jul 1-Aug 1-Sep 1-Oct 1-Nov 1-Dec 1-Jan 1-Feb 1-Mar

Fig. 12. Test positivity proportion averaged over a two-week period at the national level in
Indonesia, as of 28 March 2021, classified by level of community transmission (CT): CT1: low
incidence; CT2: moderate incidence; CT3: high incidence; CT4: very high incidence. Source of
data
Disclaimer: Caution should be exercised when interpreting this indicator due to limitations listed
in the WHO interim guidance. Other epidemiological indicators also need to be evaluated to
determine the level of community transmission.

10
WHO Indonesia Situation Report - 49
who.int/indonesia
 8.00 55.0%
People tested/1000 population/week

50.0%
7.00
45.0%

Positivity proportion (%)

6.00 40.0%
5.00 35.0%
30.0%
4.00
25.0%
3.00 20.0%
2.00 15.0%
10.0%
1.00
5.0%
- 0.0%
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
Indonesia DKI West Central DI Yogyakarta East Banten
Jakarta Java Java Java

People tested/1000 population/week Test positivity proportion

8.00 55.0%
People tested/1000 population/week

50.0%
7.00
45.0%

Positivity proportion (%)

6.00 40.0%
5.00 35.0%
30.0%
4.00
25.0%
3.00 20.0%
2.00 15.0%
10.0%
1.00
5.0%
- 0.0%
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
Indonesia West East West Riau Central South Southeast
Sumatra Kalimantan Papua Kalimantan Sumatra Sulawesi

People tested/1000 population/week Test positivity proportion

Fig. 13. Test positivity proportion and people tested per 1000 population per week at the national
level and in select provinces.

Week 1: 08/03/21 to 14/03/21; Week 2: 15/03/21 to 21/03/21; Week 3: 22/03/21 to 28/03/21

Benchmark: one person tested per 1000 population per week
Threshold test positivity proportion: <5%
Source of data: Indonesia, DKI Jakarta, West Java, Central Java, DI Yogyakarta, East Java,
Banten, West Sumatra, East Kalimantan, West Papua, Riau, Central Kalimantan, South Sumatra,
Southeast Sulawesi

Note: Due to a limitation in data, other provinces could not be evaluated. For surveillance purposes, test
positivity proportion is calculated as the number of confirmed cases divided by the number of people
tested for diagnosis.

11
WHO Indonesia Situation Report - 49
who.int/indonesia
 • During the week of 22 to 28 March, DKI Jakarta had the highest weekly number of
confirmed COVID-19 deaths per 100 000 population, followed by Bali, East
Kalimantan, North Kalimantan, and Bangka Belitung Islands (Fig. 14).

DKI Jakarta
Bali
East Kalimantan
North Kalimantan
Bangka Belitung Islands
DI Yogyakarta
South Kalimantan
East Java
Central Java
Central Sulawesi
West Java
Banten
Lampung
East Nusa Tenggara
Riau
West Papua
Gorontalo
Central Kalimantan
North Maluku
South Sumatra
West Sumatra
Riau Islands
South Sulawesi
Papua
North Sumatra
Maluku
Bengkulu
West Sulawesi
Southeast Sulawesi
West Nusa Tenggara
Aceh
Jambi
North Sulawesi
West Kalimantan

0.0 0.5 1.0 1.5

Weekly number of confirmed COVID-19 deaths per 100 000 population

CT 1 (<1) CT 2 (1 - <2) CT 3 (2 - <5) CT 4 (5+)

Fig. 14. Number of confirmed COVID-19 deaths per 100 000 population per week averaged over a
two-week period by province in Indonesia during 22 to 28 March 2021, classified by level of community
transmission (CT): CT1: low incidence; CT2: moderate incidence; CT3: high incidence; CT4: very high
incidence. Source of data

Disclaimer: Based on data availability, only confirmed COVID-19 deaths have been included. As per
WHO definition, however, death resulting from a clinically compatible illness in a probable or confirmed
COVID-19 case is a COVID-19-related death, unless there is a clear alternative cause of death that cannot
be related to COVID-19 (e.g. trauma); there should be no period of complete recovery between the illness
and death.
12
WHO Indonesia Situation Report - 49
who.int/indonesia
 • During the week of 22 to 28 March, the number of confirmed COVID-19 deaths was
0.38 per 100 000 population8, compared to 0.42 per 100 000 in the previous week
(Fig. 15).

0.8

0.7
Deaths per 100 000 population

0.6

0.5

0.4

0.3

0.2

0.1

0.0
13/04 - 19/04
27/04 - 03/05
11/05 - 17/05
25/05 - 31/05
08/06 - 14/06
22/06 - 28/06
06/07 - 12/07
20/07 - 26/07
03/08 - 09/08
17/08 - 23/08
31/08 - 06/09
14/09 - 20/09
28/09 - 04/10
12/10 - 18/10
26/10 - 01/11
09/11 - 15/11
23/11 - 29/11
07/12 - 13/12
21/12 - 27/12
04/01 - 10/01
18/01 - 24/01
01/02 - 07/02
15/02 - 21/02
01/03 - 07/03
15/03 - 21/03
Fig. 15. Number of confirmed COVID-19 deaths per 100 000 population per week averaged over a
two-week period in Indonesia, as of 28 March 2021. Source of data

Disclaimer: Based on data availability, only confirmed COVID-19 deaths have been included. As
per WHO definition, however, death resulting from a clinically compatible illness in a probable or
confirmed COVID-19 case is a COVID-19-related death, unless there is a clear alternative cause
of death that cannot be related to COVID-19 (e.g. trauma); there should be no period of complete
recovery between the illness and death. Evaluation of the level of community transmission could
not be conducted due to data limitations.

• Out of six provinces in Java, only DKI Jakarta showed a consecutive decline over
the last three weeks in the number of deaths in confirmed and probable cases
(Fig. 16).

8
Weekly mortality of COVID-19 is calculated as the number of COVID-19 deaths per 100 000 population per week
averaged over a two-week period. Source of population data
13
WHO Indonesia Situation Report - 49
who.int/indonesia
 400 DKI Jakarta 300 West Java
45
300 15
80 200 6
200 171 142
100 203 197 218
100 236
134 144
0 0
08/03/2021 - 15/03/2021 - 22/03/2021 - 08/03/2021 - 15/03/2021 - 22/03/2021 -
14/03/2021 21/03/2021 28/03/2021 14/03/2021 21/03/2021 28/03/2021

Deaths in confirmed cases Deaths in probable cases Deaths in confirmed cases Deaths in probable cases

300 Central Java 40 DI Yogyakarta

200 30

290 287 20 37
100 193 28
10 22

0 0
08/03/2021 - 15/03/2021 - 22/03/2021 - 08/03/2021 - 15/03/2021 - 22/03/2021 -
14/03/2021 21/03/2021 28/03/2021 14/03/2021 21/03/2021 28/03/2021

Deaths in confirmed cases Deaths in confirmed cases

250 East Java 50 Banten

200 9 40 1
19
13 1
150 30
2
100 176 197 20 38
160 31
50 10 24

0 0
08/03/2021 - 15/03/2021 - 22/03/2021 - 08/03/2021 - 15/03/2021 - 22/03/2021 -
14/03/2021 21/03/2021 28/03/2021 14/03/2021 21/03/2021 28/03/2021
Deaths in confirmed cases Deaths in probable cases Deaths in confirmed cases Deaths in probable cases

Fig. 16. Deaths among confirmed COVID-19 cases and probable cases per week over three weeks between
8 to 28 March 2021 in Java. Source of data: DKI Jakarta, West Java, Central Java, DI Yogyakarta, East
Java, Banten

Disclaimer: The data are provisional. There may be a discrepancy in the number of deaths in confirmed
COVID-19 cases between national and provincial data sources.

14
WHO Indonesia Situation Report - 49
who.int/indonesia
 HEALTH OPERATIONS

• As reported on 31 March, the daily number of people tested for COVID-19 was
45 714 and the cumulative number of people tested was 8 490 864 (Fig. 17).

80000 9000000
70000 8000000

60000 7000000

Cumulative number
6000000
Daily number

50000
5000000
40000
4000000
30000
3000000
20000 2000000
10000 1000000
0 0

18-Nov

5-Jan
7-Mar

8-Apr

4-Dec
14-Aug

15-Sep

22-Feb
21-Jan
24-Apr
10-May
26-May

30-Aug
23-Mar

13-Jul
29-Jul

1-Oct

2-Nov

20-Dec

6-Feb
11-Jun
27-Jun

10-Mar
26-Mar
17-Oct

Daily number of people tested Cumulative number of people tested

Fig. 17. Daily and cumulative number of people tested for COVID-19 in Indonesia,
as of 31 March 2021. Source of data

• As of 31 March, the proportion of people recovered among the total confirmed

COVID-19 cases was 89.2% and there were 122 524 active cases (Fig. 18).

200000 100.0

80.0
150000

Percentage (%)
Number

60.0
100000
40.0
50000
20.0

0 0.0
12-Nov
27-Nov

25-Feb
1-Apr

1-May

13-Sep
28-Sep

10-Feb
16-May

11-Jan
26-Jan
15-Jun
30-Jun
16-Apr

31-May

14-Aug
29-Aug

12-Dec
27-Dec

12-Mar
27-Mar
15-Jul
30-Jul

13-Oct
28-Oct

Active cases Recovery percentage

Fig. 18. Number of active cases of COVID-19 and recovery percentage in Indonesia,
as of 31 March 2021. Source of data
15
WHO Indonesia Situation Report - 49
who.int/indonesia
 • The reported number of confirmed COVID-19 cases hospitalized in DKI Jakarta
reached a peak of 9888 hospitalized cases on 12 February. The number of
hospitalized cases has since decreased to 3830 on 28 March (Fig. 19).

12000
Number of confirmed COVID-

10000
19 cases hospitalized

8000
6000
4000
2000
0
1-Jul

9-Oct

8-Dec
19-Sep
29-Sep

8-Nov

16-Feb
26-Feb
17-Jan
27-Jan

8-Mar
9-Sep

6-Feb
10-Aug
20-Aug
30-Aug

18-Nov
28-Nov

7-Jan
11-Jul
21-Jul
31-Jul

18-Mar
28-Mar
19-Oct

18-Dec
28-Dec
29-Oct
Fig. 19. Number of confirmed COVID-19 cases hospitalized in DKI Jakarta from 1 July 2020 to
28 March 2021. Source of data

Disclaimer: Data from Wisma Atlet are not included.

LABORATORY

• WHO continues to support the National Institute of Health Research and

Development (NIHRD) to strengthen quality assurance systems in COVID-19
testing laboratories (more information can be found in WHO Situation Report 34
(pages 14 to 16) and Situation Report 37 (page 16)). A total of 177 COVID-19
polymerase chain reaction (PCR) testing laboratories participated in the first phase
of the External Quality Assessment (EQA), which was supported by the Royal
College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP),
United States Agency for International Development (USAID) and WHO. The
submission of EQA results was finalized on 15 March. From 24 to 26 March, WHO
supported NIHRD to conduct supportive supervision visits to several laboratories
identified based on the preliminary analysis of the EQA results. The visit was
conducted to identify possible causes of problems in laboratory practices and to
provide recommendations for corrective actions. Continuous supervision and
technical assistance will be provided to underperforming laboratories to improve
their quality management systems to reach the national standards.

16
WHO Indonesia Situation Report - 49
who.int/indonesia
 RISK COMMUNICATION

• WHO is regularly translating and sharing important health messages on its website
and social media platforms – Twitter and Instagram – and has recently published:

Videos:
- Science in 5: Evolution of the SARS-CoV-2 virus

RISK AND NEEDS ASSESSMENT, AND PLANNING

• On 29 March, WHO supported MoH to conduct a training on contact tracing and

use of selected indicators to guide the adjustment of PHSM for East Kalimantan.
A total of 38 participants from the provincial health office (PHO) and district health
offices (DHOs) participated in the training.

• On 27 March, WHO participated in a meeting organized by MoH to discuss a

strategy and action plan to respond to the surge of COVID-19 cases in
communities living around ground crossings between Papua province of Indonesia
and Papua New Guinea. Several actions to improve and strengthen the response
in Papua were recommended, including: (i) mobilizing resources to improve testing
(including provision of PCR reagents and antigen-detecting rapid diagnostic tests
(Ag-RDTs) and increasing human resources for laboratory testing); (ii)
strengthening contact tracing activities by involving multiple stakeholders
(including armed forces, Indonesian Red Cross Society, universities, and
professional organizations); and (iii) accelerating vaccination to improve vaccine
coverage. In addition, the meeting concluded that there is a need to increase
hospital bed capacity in the province to be prepared for the surge of cases.

• On 25 March, WHO supported MoH to conduct a virtual session to review the

implementation of the Electronic Health Alert Card (eHAC) in East Java and
provide a refresher training on the eHAC application. The review found that not all
districts in the province have access to the application to keep track of travellers.
In addition, the number of travellers who have completed the eHAC remains
relatively low. MoH will continue to improve the implementation of eHAC to support
screening of travellers and contact tracing efforts.

17
WHO Indonesia Situation Report - 49
who.int/indonesia
Fig. 20. A virtual meeting to review the implementation of the Electronic Health Alert Card (eHAC)
in East Java, organized by the Ministry of Health on 25 March 2021. Credit: WHO/Endang
Wulandari

VACCINATION

• As of 29 March, 10 766 490 vaccine doses have been administered to health

workers, essential public service workers and older people (above 60 years old) in
the national COVID-19 vaccination campaign; 7 435 851 people have received the
first dose and 3 330 639 people have received the second dose (Fig. 21).
12000000

10000000
Number vaccinated

8000000

6000000

4000000

2000000

0
1-Feb
3-Feb
5-Feb
7-Feb
9-Feb
11-Feb
13-Feb
15-Feb
17-Feb
19-Feb
21-Feb
23-Feb
25-Feb
27-Feb
1-Mar
3-Mar
5-Mar
7-Mar
9-Mar
11-Mar
13-Mar
15-Mar
17-Mar
19-Mar
21-Mar
23-Mar
25-Mar
27-Mar
29-Mar
22-Jan
24-Jan
26-Jan
28-Jan
30-Jan

Cumulative 1st dose vaccination Cumulative 2nd dose vaccination

Fig. 21. Cumulative number of vaccine doses administered in Indonesia, from 22 January to
29 March 2021. Source of data

Disclaimer: COVID-19 vaccination started on 13 January. Published data from MoH is available
starting from 22 January.
18
WHO Indonesia Situation Report - 49
who.int/indonesia
 • As of 29 March, the number of health workers who have received the second dose
of the COVID-19 vaccine (fully vaccinated) was 1 275 981 (86.9% of the target
population of 1 468 764). The number of essential public service workers who have
received the first dose of the vaccine was 4 549 721 (26.3% of the targeted
17 327 169); and the number of older people who have received the first dose of
the vaccine was 1 453 977 (6.8% of the targeted 21 553 118) (Fig. 22).

Essential public service 4549721

workers 1936112

1432153
Health workers
1275981

1st dose
1453977
Older people 2nd dose
118546

0 500000 1000000 1500000 2000000 2500000 3000000 3500000 4000000 4500000 5000000

Number of people who have received COVID-19 vaccine

Fig. 22. Cumulative number of people who have received COVID-19 vaccine in Indonesia,
as of 29 March 2021. Source of data

Disclaimer: COVID-19 vaccination started with health workers on 13 January. The second
stage of COVID-19 vaccination started on 17 February, targeting essential public service
workers and older people (above 60 years old). Published data from MoH is available
starting from 22 January.

CONTINUITY OF ESSENTIAL HEALTH SERVICES

• To commemorate World Tuberculosis (TB) Day on 24 March, MoH organized a

virtual event in collaboration with the Office of the Vice President and the
Coordinating Ministry for Human Development and Cultural Affairs. Adapted from
the global theme of World TB Day 2021 “The Clock is Ticking”, the theme of the
national commemoration was “Every Second is Precious, Save the Nation from
Tuberculosis”. The theme was intended to remind relevant stakeholders and the
public that focusing on TB elimination efforts despite the COVID-19 pandemic still
remains critical. During the event, the Vice President highlighted the importance of
strengthening the national commitment and collective efforts in the fight against
TB. The Director of the WHO Global TB Programme Dr Tereza Kasaeva attended
the session and showed her appreciation for Indonesia’s efforts against TB during
the pandemic.
19
WHO Indonesia Situation Report - 49
who.int/indonesia
 Fig. 23. Infographics from the World Tuberculosis (TB) Day 2021 campaign with the global
theme “The Clock is Ticking”, May 2021. Credit: WHO

• During a virtual event to commemorate World TB Day organized by WHO on

24 March, the Minister of Health delivered a speech reiterating Indonesia’s
commitment towards TB elimination by 2030. Indonesia’s three main strategies to
improve TB notification and treatment include: (i) advancing TB screening,
diagnosis and treatment; (ii) ensuring the availability and continuity of essential TB
services for all Indonesian citizens; and (iii) ameliorating a multisectoral
collaboration in the fight against TB. In line with the joint movement to end TB
which was declared by President Joko Widodo in 2020, Indonesia is aiming to
reduce TB incidence to 219 per 100 000 population and TB mortality to 27 per
100 000 population by 2024.

• On 24 March, the National TB Programme launched a new application called

“Dashboard TB Indonesia”. The application intends to provide a platform for health
officers and stakeholders to easily and swiftly monitor the programmatic
achievements based on relevant indicators that are aligned with the National TB
Programme and Global TB Report indicators. The application is also accessible to
the public and it serves to raise public awareness on TB in the country.

20
WHO Indonesia Situation Report - 49
who.int/indonesia
 PARTNER COORDINATION

• The overall funding request for WHO operations and technical assistance is
US$ 46 million (US$ 27 million for response and US$ 19 million for recovery
phase), based on estimated needs as of March 2021 (Fig. 24)

Fig. 24. WHO funding situation for COVID-19 response, March 2021

Data presented in this situation report have been taken from publicly available data from the MoH
(https://infeksiemerging.kemkes.go.id/), COVID-19 Mitigation and National Economic Recovery
Team (KPCPEN) (http://covid19.go.id) and provincial websites. There may be differences in
national and provincial data depending on the source used. All data are provisional and subject to
change.

21
WHO Indonesia Situation Report - 49
who.int/indonesia
RECENT AND UPCOMING WHO RESOURCE MATERIALS

Table 1: Title and details of recent WHO resource materials

Source: https://www.who.int/

Title Details
WHO-convened In May 2020, the World Health Assembly in resolution
global study of WHA73.1 requested the Director-General of WHO to continue
origins of SARS- to work closely with the World Organization for Animal Health
CoV-2: China Part (OIE), the Food and Agricultural Organization of the United
(joint report), Nations (FAO) and countries to identify the zoonotic source of
30 March 2021 SARS-CoV-2 and the route of introduction to the human
population, including the possible role of intermediate hosts.

Operational This document provides practical guidance to Global Influenza

considerations to Surveillance and Response System (GISRS) laboratories and
expedite genomic other national laboratories to move beyond virus detection to
sequencing genomic sequencing of SARS-CoV-2 PCR positive materials
component of GISRS obtained from sentinel surveillance of influenza-like illness (ILI),
surveillance of acute respiratory infection (ARI) and severe acute respiratory
SARS-CoV-2, infection (SARI).
30 March 2021

Episode 31 of WHO Director of Immunization, Vaccines and Biologicals Dr

Science in 5, WHO’s Katherine O’ Brien answers questions related to COVID-19
series of vaccines, variants and vaccine doses.
conversations in
science, 26 March
2021

COVID-19 new This draft report is a summary of presentations and panel

variants: Knowledge discussions of the WHO ad hoc consultation to discuss the
gaps and research development of a research and development agenda in
(draft meeting response to the existing and emerging SARS-CoV-2 variants,
report), 25 March organized on 12 January 2021.
2021
Evaluation of This document provides interim best practice guidance on how
COVID-19 vaccine to assess COVID-19 vaccine effectiveness (VE) using
effectiveness, observational study designs. It discusses critical considerations
17 March 2021 in the design, analysis and interpretation of COVID-19 VE
evaluations. This interim guidance is targeted mainly to
evaluations undertaken in low- and middle-income countries
but most of the concepts also apply to VE evaluations in
high-income settings.

22
WHO Indonesia Situation Report - 49
who.int/indonesia
A SNAPSHOT OF WHO COURSES AND INFORMATION MATERIAL
Online WHO COVID-19 courses:
• COVID-19 vaccination training for health workers
• Standard precautions: Environmental cleaning and disinfection
• Management of COVID-19 in long-term care facilities
• Operational planning guidelines and COVID-19
• Clinical management of severe acute respiratory infections
• Health and safety briefing for respiratory diseases – eProtect

WHO guidance:
• Interim guidance for developing a Smart
Vaccination Certificate
• A guide to contracting for health services
during the COVID-19 pandemic
(conference copy)
• Interim recommendations for the use of
the Janssen Ad26.COV2.S (COVID-19)
vaccine
• Background document on the Janssen
Ad26.COV2.S (COVID-19) vaccine

Infographics:
• Contact tracing
• COVID-19 new variants
• COVID-19 vaccines and vaccination
• The truth about COVID-19 vaccines
• Quarantine and self-monitoring
• COVID-19 tests

Questions and answers:

• COVID-19: Vaccines
• COVID-19: Vaccine research and development
• COVID-19: Vaccine access and allocation
• How are vaccines developed?

Videos:
• Time to abide (1-10)
• Hand sanitizer routine
• COVID-19 virus variants
• Science in 5: “I am vaccinated, what next?”

For more information please feel free to contact: seinocomm@who.int

WHO Indonesia Reports

23
WHO Indonesia Situation Report - 49
who.int/indonesia